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Good syndrome (GS) or thymoma-associated immunodeficiency, is a rare condition that has only been studied in
retrospective case series. General consensus was that GS has a worse prognosis than other humoral immunode-
ficiencies. In this study, physicians of GS patients completed two questionnaires with a two year interval with
data on 47 patients, 499 patient years in total. Results on epidemiology, disease characteristics, and outcome
are presented. Mean age at diagnosis was 60 years and median follow-up from onset of symptoms was
9 years. There was a high frequency of respiratory tract infections due to encapsulated bacteria. Median survival
was 14 years. Survival was reduced compared to age-matched population controls (5-year survival: 82% versus
95%, p=0.008). In this cohort survivalwas not associatedwith gender (HR 0.9, 95% CI 0.3–3.0), autoimmune dis-
eases (HR 2.9, 95% CI 0.8–10.1) or immunosuppressive use (HR 0.3, 95% CI: 0.1–1.2).
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
In 1954 Robert Good described three patients with thymoma and
hypogammaglobulinemia [1]. Today, the condition is designated as
Good syndrome (GS) [1]. It is typically an adult-onset immunodeficiency
rendering patients susceptible to bacterial, viral, fungal and opportunis-
tic infections. Immunological features of GS include hypogamma-
globulinemia, a reduction in peripheral B-cells, CD4+ lymphopenia
and reversal of CD4/CD8 ratio. In one series comprising 18 thymoma pa-
tients, whose immunophenotype was assessed, 12 patients were found
to have immunological abnormalities such as B-cell and T-cell lympho-
penia, whereas hypogammaglobulinemia was found in only 4 patients
[2]. So far, GS has only been studied retrospectively in case reports and
small retrospective case series. Therefore, the course of disease is not
well understood. Reviews suggest that GS has a worse prognosis than
other immunodeficiencies [3] with amortality of 44.5% [4] to 57% [5], al-
though follow-up time is unclear. In the present study, performed in
2012 and 2014, we collected new data, to assess the course and progno-
sis of GS by means of a prospective cohort study.
2. Methods
2.1. Subjects
Due to lack of diagnostic criteria and differing definitions in the
literature, the following inclusion criteria were employed: ‘Classical
Good syndrome’: patients with a combination of a thymoma and
hypogammaglobulinemia. ‘Probable Good syndrome’: patients who ei-
ther have thymoma or thymic carcinoma and any unclassified immuno-
deficiency, but do not meet the criteria for classical Good syndrome.
Patient data were collected in two ways. A PubMed search was
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conducted applying the terms ‘thymoma’ and ‘immunodeficiency’. Arti-
cles dating back to 1984 written in English, German and French were
assessed for suitability. This yielded 53 articles describing 67 patients.
All 53 corresponding authors were sent an anonymised questionnaire
regarding their patients, and were also asked to include any other pa-
tients that they had under their care. In addition, the European Society
for Immunodeficiencies (ESID) facilitated us to contact all 13 centers
that had registered patients with GS in the ESID online database. We
asked them to complete the same anonymised questionnaire for the
54 patients that were registered. The questionnaires were sent out in
2012 (n= 53+ 13). In 2014 we sent a second questionnaire to the au-
thors (n=12) and centers (n=5) that responded to thefirst question-
naire and reported data of non-deceased patients.
This study did not fall under the Medical Research Involving Human
Subjects Act (WMO) because it concerned anonymised data from pa-
tient records, and therefore did not need to undergo a medical ethical
review.
2.2. Instruments
In the first questionnaire, data was collected on age, gender, age at
diagnosis characteristics of the thymoma associated infections and au-
toimmune disease alongside immunological parameters, therapy and
course of the disease so far. Two years later, a follow-up questionnaire,
focusing on the course of the disease since the first questionnaire, was
compiled consisting of questions about thymoma recurrence, hospital
admissions, infections and the development of malignancy.
2.3. Statistical analysis
Statistics were performed using Graphpad Prism v5.03. A p-value of
b0.05was considered statistically significant. Descriptive statisticswere
generated (mean, standard deviation, median and range) where appli-
cable and the frequency distribution was calculated for categorical
data. The Wilcoxon signed rank test was used to calculate differences
when medians were provided, whereas categorical data was analysed
with the Fisher's exact test. Correlation was assessed using Spearman's
rank correlation coefficient and survival analysis was performed with
the Kaplan Meier analysis. Probabilities of survival after diagnosis of
GS were compared to the expected survival of the general population
of similar mean age, based on the European life tables from 2005 [6].
Differences in survival were assessed with the Log-Rank test. A multi-
variate Cox regression analysis was performed, using the fixed covari-
ates gender, immunosuppressives use (including periodically used
steroids) and presence of autoimmune diseases at any time during the
course of the disease. The hazard ratios (HR) and the 95% confidence in-
tervals were calculated.
3. Results
The 2012 questionnaire was completed and returned by 12 authors
(response rate 23%) and 5 centers (38%) and comprised 18 and 29 (total
47) patients respectively. Patients originated from different countries as
is shown in Table 1. Of these 47 patients, 35 were alive and 12 were de-
ceased. The 2014 questionnaire was returned by 7 authors (response
rate 58%) and 5 centers (100%) and comprised follow-up data of 27 pa-
tients, 23 of them were still alive and 4 had succumbed in the last
2 years. See Fig. 1.
3.1. Baseline characteristics
Median age at diagnosiswas 58 years (range 38 to 85 years)with the
exclusion of one paediatric case (detailed below). No significant differ-
ence was found between men and women in terms of age at diagnosis.
There were 23 men and 24 women at baseline; in the second question-
naire, men represented 44% (of 27 patients). The median age at
diagnosis of the thymoma was 58 years (range 30–80 years) and the
median age relating to the start of infections was 57 years (range 31–
82). In 5 patients (11%) the thymoma was the first sign of GS, in 20 pa-
tients (42%) the symptoms started almost simultaneously (within a
year) and infections preceded the diagnosis of the thymoma in 19 pa-
tients (40%). The mean delay in diagnosis was 3.1 years (range 0 to
17 years), with a median of 1 year. There was no correlation between
the first sign (thymoma or infections) and the duration of delay. We
had a total follow-up of 498.8 patient years, with a median of 9 years
per patient (range 0.25–27 years), from onset of symptoms to the
final data collected.
The paediatric case involved an eleven-year-old patient with a
thymoma and hypogammaglobulinemia. Infections started at 6 years
of age. This patient is of unusually young age for GS and does meet the
classic criteria for this condition. Only one paediatric case of GS has
been described in the literature [7].
3.2. Thymoma
Thymoma was an incidental finding on a CT or X-ray in 41% of pa-
tients; in 59% (of 44 patients) symptoms prompted diagnostic investiga-
tions (CT-scan or X-ray). These symptoms included: chronic or
persistent cough (n = 10), shortness of breath (n = 3), weight loss
(n = 3), respiratory tract infections (n = 7), and other symptoms such
as superior vena cava obstruction (n = 1) or sternal pain (n = 1). In
three cases an associated autoimmune syndrome or paraneoplastic syn-
dromewas the reason for the diagnostic workup for thymoma. Themost
commonly found type according to theWHO system of thymomawas A
(37.8%), other types such as B (all subtypes), AB and C were found in
24.3%, 35.1%, and 2.7% of patients respectively, froma total of 37 patients.
3.3. Immunodeficiency and infections
All patients presented with marked hypogammaglobulinemia
(Table 2), often accompanied by decreased or absent numbers of circu-
lating B-cells. Only two patients (of 38 patients) presented with a B-cell
count ofmore than 200×106/l. Reduced numbers of CD4+T-cells were
reported in 62% of patients, usually mild, while 20% had a frank CD4+
T-cell lymphopenia.
Only one patient with classical GS had not experienced infections at
the time of the first questionnaire (5 years of follow-up). Thirty-five pa-
tients (74%) had at least one lower respiratory tract infection, which
was themost frequently reported infection followed byupper respirato-
ry tract infections (n = 25). Seventeen patients had gastrointestinal
tract infections (36%), 10 patients had infections of skin and soft tissue
(21%), 7 patients had urinary tract infections (15%), 5 systemic infec-
tions (11%) and 15 (32%) had other infections which consisted mostly
Table 1
Country of origin.
Country Total number of included
GS patients
Europe
United Kingdom 13
Spain 7
Czech Republic 5
The Netherlands 4
Finland 4
France 1
Germany 1
Poland 1
Asia
Japan 7
China 3
USA 1
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of (encephalo)-meningitis and conjunctivitis. This same pattern of in-
fections was reported in the follow-up questionnaire two years later.
As regards the causative micro-organism, bacterial infections were
most common (80% of patients) but 23% of patients had encountered
viral infections and 26% fungal infections (Fig. 2). Table 3 provides a
list of known pathogens reported in both questionnaires. CMV, Asper-
gillus and Candida infections, occurring in 15 patients of which 6 were
treatedwith corticosteroids or other immunosuppressives, were not as-
sociated with a lower CD4+ T-cells number (p = 0.91). Whether Can-
dida infections, which were mostly oral or vaginal, occurred after
antibiotic use was not recorded.
3.4. Autoimmune disorders
Twenty-four patients (51%) had an autoimmune disease and 8 pa-
tients had N1 autoimmune disease. Pure red cell aplasia (8 patients)
was the most frequent autoimmune disease, followed by lichen planus
(7 patients). Other autoimmune diseases that were reported multiple
times weremyasthenia gravis and aplastic anemia. Thirteen other auto-
immune diseases were reported only once (Table 4). In the second
questionnaire, 2 patients out of 27 had developed a new autoimmune
disease in the 2 years follow-up since the baseline questionnaire: one
case of hypothyroidism and one case of subacute cutaneous lupus.
There was no significant difference in the types of thymoma between
the patients with and without autoimmune manifestations.
3.5. Management and prognosis
Forty-four patients (93.6%) received immunoglobulin supplementa-
tion and 29 patients (63.0%) received some form of antibiotic prophy-
laxis. Most patients did not have other treatment, although 27.7%
were treated with immunosuppressive agents and 8.5% received G-CSF.
The baseline questionnaire also assessed the clinical course of disease
from diagnosis along with the patients current status (with a median of
8 years after onset of symptoms). Inmost patients, the immunodeficien-
cy they presented with remained stable over the follow-up period. Fifty-
five percent of patients were reported to still have frequent infectious
diseases, while 9% of patients were asymptomatic. Of all patients with
data on the course of the autoimmune disease (17 patients), 18% of pa-
tients had improvement of the autoimmune disease, in 47% there was
no change and in 35% the disease had deteriorated.
Five patients developed a malignancy. The reported malignancies
were skin cancer (2), large granular T-cell lymphoma, thyroid cancer
and one unknown malignancy. A single patient had a recurrence of
the thymoma, initialWHO type A, approximately 5 years after the initial
diagnosis.
During the 2 years of follow up until the second questionnaire, 8 pa-
tients (32%) were admitted to hospital at least once and 19 patients
(76%) reported infections. One patient had 4 hospital admissions due
to seizures, thrombocytopenia and secondary hemochromatosis after
frequent transfusions. Three patients had a hospital admission due to
probable infections (sepsis, lower respiratory tract infection, suspected
Fig. 1. Loss to follow up. Abbreviations: ESID: European Society for immunodeficiencies. 12 casereports references: [23–34].
Table 2
Laboratory values.
Laboratory values N Median Range Median general population p-Value median
IgG 45 228.0 mg/dl 7.0–666.0 1090 mg/dl b0.001*
IgA 47 25.0 mg/dl 1.0–180.0 239 mg/dl b0.001*
IgM 47 10.0 mg/dl 0–49.0 134 mg/dl b0.001*
B-cells 38 0.0 × 106/l 0.0–406.0 200 × 106/l b0.001*
CD4+ T-cells 36 565.0 × 109/l 65.0–2390 700 × 106/l 0.02*
Hemoglobin 33 12.9 g/dl 8.1–16.1 14.1 g/dl b0.001*
Hemoglobin male 16 13.0 g/dl 8.1–16.1 14.9 g/dl 0.002*
Hemoglobin female 17 12.6 g/dl 14.2–10.7 13.4 g/dl 0.01*
Thrombocytes 37 279.0 × 109/l 33.0–617.0 260 × 109/l 0.53
Neutrophils 42 385.0 × 107/l 0.0–2673 – –
Natural Killer cells 28 155.0 × 106/l 102.0–301.0 300 × 106/l 0.06
Table 2 Reference values: Gonzalez-Quintela 2007 [20] for immunoglobulins, Comans 1997 for B-cells [21], T-cells and NK-cells, Hollowell 2005 for other laboratory values [22]. Medians
are derived from average medians for patients of 40 years and older. Patients from our cohort with autoimmune anemia are excluded as well as patients with autoimmune thrombocy-
topenia, * = p b 0.05; significantly different from normal median.
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neuroborreliosis). In 2 patients the hospital admissionwas not specified
and the other two patients were under investigation for diarrhea or had
a head injury.
Total number of deaths was 16 out of 39 patients (41%), including 12
patients that died before completion of the first questionnaire and 4 pa-
tients who died during the 2 year follow-up period. The median age at
time of death was 69 years (range 46–96 years). Death was attributed
to infection or cardiovascular disease in 3 of these patients. The cause
of death was miscellaneous, 25% (4 patients) died of an infection and 3
of cardiovascular disease. Two patients died of ‘old age’ and in 4 patients
the cause of death was unknown. One patient died of complications of
aplastic anemia and one patient died as a result of malabsorption. Meta-
static thymoma was the cause of death in one 80-year-old patient, who
passed away 6 years after the initial diagnosis of the thymoma, which
was a WHO type B. The Kaplan Meier survival analysis (Fig. 3a) shows
a 5-year survival of approximately 82% and 10-year survival of 68%.
Themedian survival is 14 years.With amultivariate CoxRegression anal-
ysis, the effect on mortality of immunosuppressives use (no n = 30, yes
n = 13, HR: 0.3, 95% CI: 0.1–1.2) and the presence of autoimmune dis-
eases (no n= 22, yes n= 21, HR 2.9, 95% CI 0.8–10.1) was determined.
Gender (man n= 20, woman n= 23) was not associated with a signif-
icantly higher mortality (HR 0.9, 95% CI 0.3–3.0).
Fig. 2. Reported pathogens in questionnaire 1.
Table 3
Reported pathogens.
Pathogens Number of patients
Q1 (% of 91 reported pathogens)
Number of patients
Q2 (% of 15 reported pathogens)
Additional remarks
Bacteria/mycobacteria
Haemophilus influenzae 18 (20%) 4 (27%)
Streptococcus pneumoniae 12 (13%) 1 (7%)
Pseudomonas 7 (8%) 4 (27%)
Campylobacter 7 (8%)
Staphylococcus 3 (3%) 1
Escherichia coli 3 (3%) 1 (7%)
Moraxella 3 (3%) 1 (7%)
Clostridium difficile 2 (2%)
Klebsiella 2 (2%) Bronchitis/pneumonia
Proteus mirabilis 1 (1%)
Enterobacter asburiae 1 (1%)
Mycobacterium chelonae 1 (1%) Lower respiratory tract
Ureaplasma 1 (1%)
Bacteroides fragilis 1 (1%)
Francisella tularensis 1 (1%) Abscesses
Enterococcus faecium 1 (1%) Sepsis
Viruses
Cytomegalovirus 6 (7%) 1 (7%)
Herpes simplex virus 3 (3%) 1 meningitis
Hepatitis C virus 1 (1%)
Respiratory syncytial virus 1 (1%)
Varicella zoster virus 1 (1%)
Fungi
Candida 9 (10%) 2 (13%) Mostly oral or vaginal
Aspergillus 1 (1%)
Tinea 1 (1%)
Pneumocystis jiroveci 1 (1%) Pneumonia
Other
Toxoplasma 1 (1%) Retinochoroiditis
Blastocystis hominis 1 (1%)
Giardia lamblia 1 (1%)
Table 3 Abbreviations: Q1=baseline questionnaire, which reported all infections up until the date of the questionnaire; Q2= follow-up questionnaire, which reported infections in the 2
years since the baseline questionnaire.
Table 4
Reported autoimmune diseases.
Autoimmune disorders Number of patients
(% of 33 reported
autoimmune disorders)
Pure red cell aplasia 8 (24.2%)
Lichen planus 7 (21.2%)
Myasthenia gravis 3 (9.1%)
Aplastic anemia 2 (6.1%)
Idiopathic thrombocytopenic purpura 2 (6.1%)
Athralgias and/or tenosynovitis 2 (6.1%)
Ulcerative colitis 1 (3.0%)
Celiac diseases 1 (3.0%)
Adrenal insufficiency 1 (3.0%)
Addison's disease 1 (3.0%)
Alopecia areata 1 (3.0%)
Leucopenia 1 (3.0%)
Thrombocytopenia 1 (3.0%)
Mucous membrane pemphigoid 1 (3.0%)
Vitiligo 1 (3.0%)
Rheumatoid arthritis 1 (3.0%)
Sjögren's syndrome 1 (3.0%)
Chronic urticaria 1 (3.0%)
Primary sclerosing cholangitis 1 (3.0%)
Autoimmune hemolytic anemia 1 (3.0%)
Myelo-radiculitis 1 (3.0%)
Limbic encephalitis 1 (3.0%)
Table 4 Autoimmune manifestations.
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We have also compared GS patients to the age-matched general
population according to the European life tables from2005. The survival
of patients with GS is statistically significantly reduced compared to the
age-matched normal population of 60-year-olds. The general popula-
tion has a 5-year survival of 95% compared to 82% of Good syndrome pa-
tients (p = 0.002; Fig. 3b).
4. Discussion
In our study, involving nearly 500 patient-years of follow-up in pa-
tients with GS, we found a median survival of 14 years and median
age at death of 69 years. Overall mortality in this study was 41%, with
25% of deaths being a direct result of infection, despite the fact that al-
most all patients were treated with immunoglobulin and more than
half received some form of antibiotic prophylaxis. Autoimmune disor-
ders were a significant cause of morbidity in this patient cohort, ob-
served in 51% of patients.
As previously reported by Kelesidis and Yang [4], patients with GS
are prone to bacterial, viral and fungal infections. This was confirmed
in our study by a high number of viral (23%) and fungal (26%) infections
for a predominantly humoral immunodeficiency. We found that CD4+
T-cell count was only mildly decreased in most patients. Moreover, we
were unable to detect a difference in CD4+ T-cell count in patients
with andwithout opportunistic infections. CD4+T-cell count can be in-
fluenced by different factors such as age [8,9], infection, and immuno-
suppressive therapy, so the observed decrease in CD4+ T-cell count
may not be significant. This makes a functional T-cell defect more likely
to be central to the development of viral and fungal infections than the
observed slight CD4+ lymphopenia. This is corroborated by earlier
studies on T-cell defects in Good syndrome patients [10]. Although
most physicians reported that their patients still had infections in the
2-year follow-up period, which was a median of 9 years after diagnosis,
only 3 patients had severe infections for which they were admitted to
hospital. In our patients, GS progressed heterogeneously, leading to in-
fections, autoimmune manifestations and some patients were asymp-
tomatic on immunoglobulin therapy.
We found amedian survival 14 years in 47 GS patients, which is bet-
ter than reported previously. In a study performed by Hermanszweski
dating from 1993, CVID patients were compared to patients with
thymoma associated immunodeficiency. Five years after the start of
symptoms, approximately 70% of these thymoma associated immuno-
deficiency patients (n = 7 in total) was still alive, and after 15 years
all patients had died. Thereafter, thymoma associated immunodeficien-
cy has been considered a condition with a poor prognosis, which is
markedlyworse than CVID.Only recentlyMalphettes et al. [11] reported
on survival of a cohort comprising 21 GS patients from a single center,
which was better than expected. This strengthens our observation
that although GS may have a heterogeneous course, overall survival is
better than described in previous reports.
Good syndrome shares multiple features with CVID, such as type of
immunodeficiency and autoimmune phenomena. Recently, two genetic
mutations in three patients have been identified involving two mem-
bers of the Tumor Necrosis Factor Receptor superfamily i.e. TACI protein
and BAFF-R [12–14]. Interestingly, mutations in these genes are associ-
ated with CVID in some families, although the mutations can also be
present in unaffected individuals, which suggests that these mutations
increase the risk of immunological abnormalities or are disease-
modifying rather than having a direct causative role. Differences be-
tween GS and CVID include the older age of onset, and the profoundly
reduced B-cell count. Although Good syndrome has been described as
a distinct entity because of these differences, the similarities in clinical
manifestations and the possible association with these mutations are
remarkable.
Mortality in our study was higher than in CVID, which is reported at
15% after a median of 22 follow-up years, although mortality strongly
depends on the complications [15]. The diagnostic delay in Good syn-
drome (median 1 year) is less than in CVID (median 5 years, [15]), so
this is unlikely to contribute to this difference. Median age at diagnosis
in a large study on CVID was 30 years for men and 33.5 years for
women. Their mean age at death is 44 years for men and 42 years for
women [16]. This differs fromGS patients as theirmedian age at diagno-
sis is 58 years and their mean age at death is 70 years. This large age dif-
ference will affect the prognosis. Therefore, when put into perspective,
Good syndrome mortality is likely similar to mortality of 60-year-old
CVID patients.
This study was the first to focus on course and prognosis of Good
syndrome. In contrast to other studies on Good syndrome, we used
questionnaires to collect previously unpublished data and follow up
data. A limitation of this studywas the small number of subjects,making
it hard to obtain sufficient power to analyze groups. The number of sub-
jects also was too small to detect low incidence comorbidity, such as
malignant lymphoma, which would also require a longer follow-up pe-
riod. Given the increased incidence of cancer and lymphoma in CVID pa-
tients, this may well be a feature of Good syndrome.
All patients enrolled in this study had hypogammaglobulinemia and
thusmet the criteria for classical Good syndrome. Since thefirst case de-
scribed by Dr. Good in 1954, hypogammaglobulinemia is regarded as
the most important laboratory feature of Good syndrome. However,
several studies on thymoma patients have identified patients with
other immune impairments, but with normal immunoglobulin levels.
Montella et al. [2] studied 18 thymoma patients of which 9 patients
had a B-cell lymphopenia and 4 patients had a low T-lymphocyte num-
ber, while only 4 patients had hypogammaglobulinemia. Thongprayoon
et al. [17] studied 87 thymoma patients. Eight patients with clinical
symptoms suspicious for an immunodeficiency were tested and al-
though 5 patients had an inverted CD4/CD8 ratio and 3 had B-cell
Fig. 3. KaplanMeier analysis. (a) Kaplan Meier analysis of Good syndrome (GS) and table
of subjects at risk. (b) GS compared to the general population according to the European
life tables (p = 0.002, HR 3.7, CI 1.6–8.3) [6].
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lymphopenia, only one patient had hypogammaglobulinemia. In addi-
tion, Holbro et al. [18] documented infections in 29 thymoma patients,
52% of these patients had at least one infectious episode. Some of
these infections were severe or opportunistic in the absence of immu-
nosuppressive treatment. After surgery, only one patient had low im-
munoglobulin levels and a B-cell lymphopenia. These studies show
that there are probably thymoma patients with other immune defects
than hypogammaglobulinemia. Whether these patients will in time de-
velop hypogammaglobulinemia is unclear. The International Union of
Immunological Societies Expert Committee for Primary Immunodefi-
ciency uses thymoma and immunodeficiency as definition and does
not distinguish between different immune defects [19]. Use of the dis-
tinction between ‘classic’ and ‘probable’ Good syndrome (seeMethods)
will allow further investigations, while still including all thymoma pa-
tients with immune disorders.
In conclusion, Good syndrome is a complex immunodeficiency
characterised by variable phenotype and with similarities to CVID. The
5-year mortality rate of patients with Good syndrome is higher than
that of patients with CVID, but this is more likely due to their much
higher age at diagnosis (mean 60 versus 30 years) than to overall great-
er severity of disease. The combination of a high susceptibility to a myr-
iad of infectious diseases and concomitant autoimmune diseases
requiring immunosuppressive therapy makes treating Good syndrome
a challenging task. Our study on one of the largest international cohorts
indicates that immunosuppressive therapy and autoimmune diseases
are not associated with a worse survival. Despite the challenge of infec-
tion and autoimmunity, we show that the prognosis of Good syndrome
is better than described previously.
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